226 related articles for article (PubMed ID: 17911462)
1. Natalizumab in the treatment of patients with multiple sclerosis: first experience.
Mareckova H; Havrdova E; Krasulova E; Vankova Z; Koberová M; Sterzl I
Ann N Y Acad Sci; 2007 Sep; 1110():465-73. PubMed ID: 17911462
[TBL] [Abstract][Full Text] [Related]
2. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
Stüve O; Marra CM; Bar-Or A; Niino M; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Jerome KR; Cook L; Grand'Maison F; Hemmer B; Monson NL; Racke MK
Arch Neurol; 2006 Oct; 63(10):1383-7. PubMed ID: 17030653
[TBL] [Abstract][Full Text] [Related]
3. Immune surveillance in multiple sclerosis patients treated with natalizumab.
Stüve O; Marra CM; Jerome KR; Cook L; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Hemmer B; Monson NL; Racke MK
Ann Neurol; 2006 May; 59(5):743-7. PubMed ID: 16634029
[TBL] [Abstract][Full Text] [Related]
4. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab.
del Pilar Martin M; Cravens PD; Winger R; Frohman EM; Racke MK; Eagar TN; Zamvil SS; Weber MS; Hemmer B; Karandikar NJ; Kleinschmidt-DeMasters BK; Stüve O
Arch Neurol; 2008 Dec; 65(12):1596-603. PubMed ID: 18852339
[TBL] [Abstract][Full Text] [Related]
5. The effects of natalizumab on the innate and adaptive immune system in the central nervous system.
Stüve O
J Neurol Sci; 2008 Nov; 274(1-2):39-41. PubMed ID: 18474372
[TBL] [Abstract][Full Text] [Related]
6. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
Rudick RA; Sandrock A
Expert Rev Neurother; 2004 Jul; 4(4):571-80. PubMed ID: 15853576
[TBL] [Abstract][Full Text] [Related]
7. [Natalizumab in the treatment of multiple sclerosis].
Horga A; Horga de la Parte JF
Rev Neurol; 2007 Sep 1-15; 45(5):293-303. PubMed ID: 17876741
[TBL] [Abstract][Full Text] [Related]
8. Relationship between expression of chemokine receptors CCR3, CCR5 and CXCR3 on CD4(+) T cells and spontaneous abortion in mice.
Jiang PJ; Lin QD; Bao SM; Zhao AM; Zhang Y; Xiao SJ
Chin Med J (Engl); 2009 Feb; 122(4):390-5. PubMed ID: 19302742
[TBL] [Abstract][Full Text] [Related]
9. Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid.
Mellergård J; Edström M; Vrethem M; Ernerudh J; Dahle C
Mult Scler; 2010 Feb; 16(2):208-17. PubMed ID: 20007431
[TBL] [Abstract][Full Text] [Related]
10. Differential susceptibility to apoptosis of CD4+T cells expressing CCR5 and CXCR3 in patients with MS.
Julià E; Edo MC; Horga A; Montalban X; Comabella M
Clin Immunol; 2009 Dec; 133(3):364-74. PubMed ID: 19740704
[TBL] [Abstract][Full Text] [Related]
11. Natalizumab: new drug. Multiple sclerosis: risky market approval.
Prescrire Int; 2008 Feb; 17(93):7-10. PubMed ID: 18354844
[TBL] [Abstract][Full Text] [Related]
12. Natalizumab: targeting alpha4-integrins in multiple sclerosis.
Engelhardt B; Kappos L
Neurodegener Dis; 2008; 5(1):16-22. PubMed ID: 18075270
[TBL] [Abstract][Full Text] [Related]
13. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.
Calabresi PA; Giovannoni G; Confavreux C; Galetta SL; Havrdova E; Hutchinson M; Kappos L; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Lublin FD; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA;
Neurology; 2007 Oct; 69(14):1391-403. PubMed ID: 17761550
[TBL] [Abstract][Full Text] [Related]
14. Early relapses after the first dose of natalizumab in active multiple sclerosis patients.
Centonze D; Furlan R; Gasperini C; Salvetti M; Battistini L
Mult Scler; 2008 Sep; 14(8):1137-8. PubMed ID: 18701574
[TBL] [Abstract][Full Text] [Related]
15. Multiple sclerosis: chemokine receptor expression on circulating lymphocytes in correlation with radiographic measures of tissue injury.
Fox RJ; Kivisakk P; Fisher E; Tucky B; Lee JC; Rudick RA; Ransohoff RM
Mult Scler; 2008 Sep; 14(8):1036-43. PubMed ID: 18701575
[TBL] [Abstract][Full Text] [Related]
16. Immunological markers of optimal response to natalizumab in multiple sclerosis.
Villar LM; García-Sánchez MI; Costa-Frossard L; Espiño M; Roldán E; Páramo D; Lucas M; Izquierdo G; Álvarez-Cermeño JC
Arch Neurol; 2012 Feb; 69(2):191-7. PubMed ID: 22332187
[TBL] [Abstract][Full Text] [Related]
17. Natalizumab for the treatment of multiple sclerosis and Crohn's disease.
Keeley KA; Rivey MP; Allington DR
Ann Pharmacother; 2005 Nov; 39(11):1833-43. PubMed ID: 16219898
[TBL] [Abstract][Full Text] [Related]
18. Deficient Fas expression by CD4+ CCR5+ T cells in multiple sclerosis.
Julià E; Montalban X; Al-Zayat H; Issazadeh-Navikas S; Goertsches R; Martin R; Comabella M
J Neuroimmunol; 2006 Nov; 180(1-2):147-58. PubMed ID: 16899302
[TBL] [Abstract][Full Text] [Related]
19. Natalizumab (Tysabri) treatment for relapsing multiple sclerosis.
Johnson KP
Neurologist; 2007 Jul; 13(4):182-7. PubMed ID: 17622909
[TBL] [Abstract][Full Text] [Related]
20. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS.
Sellebjerg F; Börnsen L; Khademi M; Krakauer M; Olsson T; Frederiksen JL; Sørensen PS
Neurology; 2009 Dec; 73(23):2003-10. PubMed ID: 19996075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
